Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XBIT
stocks logo

XBIT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for XBiotech Inc (XBIT.O) is 0.00, compared to its 5-year average forward P/E of 24.89. For a more detailed relative valuation and DCF analysis to assess XBiotech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
24.89
Current PE
0.00
Overvalued PE
77.18
Undervalued PE
-27.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.94
Current PS
0.00
Overvalued PS
11.03
Undervalued PS
-3.16
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XBIT News & Events

Events Timeline

(ET)
2024-12-23
08:06:21
XBiotech pauses rheumatology program
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
02-05PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

  • Investigation into XBiotech: Pomerantz LLP is investigating claims of securities fraud against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis program due to irregularities in trial results, which led to a significant drop in stock price.

  • Pomerantz LLP's Background: The firm, known for its expertise in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has secured substantial damages for class members over the years.

[object Object]
Preview
7.0
01-15Newsfilter
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

  • Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis drug candidate, Natrunix, due to irregularities in a recent clinical trial.

  • Stock Impact: The announcement led to a significant drop in XBiotech's stock price, falling over 29% from $6.38 to $4.50 per share as concerns about the study's findings and implications for future research arose.

[object Object]
Preview
7.0
01-14Globenewswire
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

  • Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis drug candidate, Natrunix, due to irregularities and failure to meet primary study endpoints.

  • Stock Impact: The announcement led to a significant drop in XBiotech's stock price, falling over 29% from $6.38 to $4.50 per share as concerns about the integrity of clinical trial data emerged.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is XBiotech Inc (XBIT) stock price today?

The current price of XBIT is 2.51 USD — it has decreased -3.09 % in the last trading day.

arrow icon

What is XBiotech Inc (XBIT)'s business?

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

arrow icon

What is the price predicton of XBIT Stock?

Wall Street analysts forecast XBIT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XBIT is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is XBiotech Inc (XBIT)'s revenue for the last quarter?

XBiotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is XBiotech Inc (XBIT)'s earnings per share (EPS) for the last quarter?

XBiotech Inc. EPS for the last quarter amounts to -0.20 USD, increased 25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for XBiotech Inc (XBIT)'s fundamentals?

The market is revising No Change the revenue expectations for XBIT for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -14.04%.
arrow icon

How many employees does XBiotech Inc (XBIT). have?

XBiotech Inc (XBIT) has 92 emplpoyees as of December 05 2025.

arrow icon

What is XBiotech Inc (XBIT) market cap?

Today XBIT has the market capitalization of 76.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free